Regulatory NewsBREAK: CMS Issues Final Negotiated Prices for Initial Price Applicability Year 2026
On Aug. 15, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the Final Negotiated Prices for Initial Price Applicability Year 2026 under the Inflation Reduction Act (IRA). The drugs selected for this negotiation are Januvia, Fiasp, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, and Embruvica. Access the Regulatory NewsBREAK to learn more.
Related
In January 2025, the U.S. Department of Health and Human Services (HHS) issued a Strategic Plan for the Use of Artificial Intelligence in Health, Human Services, and Public Health in efforts to use AI responsibly to improve people's lives.
On December 20, 2024, the Centers for Medicare & Medicaid Services (CMS) issued explanations for the maximum fair prices (MFPs) for the drugs selected for the IRA’s Medicare Drug Price Negotiation Program for the initial price applicability year (IPAY) 2026.
On Dec. 12, 2024, the Centers for Medicare and Medicaid Services (CMS) issued a final rule titled, “Modifications of Health Insurance Portability and Accountability Act of 1996 (HIPAA) National Council for Prescription Drug Programs (NCPDP) Retail Pharmacy Standards; and Modification of the Medicaid Pharmacy Subrogation Standard” (Final Rule).
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
